Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
Gates Colbert,1 Shilpa Sannapaneni,1 Edgar V Lerma2 1Department of Internal Medicine, Division of Nephrology, Texas A&M College of Medicine, Dallas, TX, USA; 2Department of Internal Medicine, Division of Nephrology, University of Illinois at Chicago College of Medicine, Chicago, IL, USACorrespon...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-07-01
|
| Series: | Drug, Healthcare and Patient Safety |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-efficacy-safety-tolerability-and-real-world-data-of-patiromer-peer-reviewed-fulltext-article-DHPS |
| _version_ | 1818534682761887744 |
|---|---|
| author | Colbert G Sannapaneni S Lerma EV |
| author_facet | Colbert G Sannapaneni S Lerma EV |
| author_sort | Colbert G |
| collection | DOAJ |
| description | Gates Colbert,1 Shilpa Sannapaneni,1 Edgar V Lerma2 1Department of Internal Medicine, Division of Nephrology, Texas A&M College of Medicine, Dallas, TX, USA; 2Department of Internal Medicine, Division of Nephrology, University of Illinois at Chicago College of Medicine, Chicago, IL, USACorrespondence: Gates Colbert, 3417 Gaston Ave, Suite 875, Dallas, TX, 75246, Tel +972-388-5970, Fax +972-388-5971, Email Gates.Colbert@BSWHealth.orgAbstract: Hyperkalemia remains one of the most difficult consequences of disease state and treatment for patients with chronic kidney disease, heart failure, and diabetes. Controlling hyperkalemia can be difficult, but has become easier with the introduction of novel oral potassium binders. Patiromer was approved in 2015 for the treatment of hyperkalemia by the FDA in the United States. Several pivotal trials proved its efficacy, safety, and improved tolerability compared with previous hyperkalemia treatments. Additionally, many real-world publications and trials have given deeper insights into the capabilities of patiromer. We discuss improved disease state outcomes with combining patiromer with RAASi. This paper will also highlight new trials forthcoming that are highly anticipated to expand the possibilities in using patiromer to improve outcomes and populations.Keywords: hyperkalemia, chronic kidney disease, patiromer, proteinuria |
| first_indexed | 2024-12-11T18:14:44Z |
| format | Article |
| id | doaj.art-d20de6f933eb49f7a5fbb6b9892655f6 |
| institution | Directory Open Access Journal |
| issn | 1179-1365 |
| language | English |
| last_indexed | 2024-12-11T18:14:44Z |
| publishDate | 2022-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug, Healthcare and Patient Safety |
| spelling | doaj.art-d20de6f933eb49f7a5fbb6b9892655f62022-12-22T00:55:28ZengDove Medical PressDrug, Healthcare and Patient Safety1179-13652022-07-01Volume 14879676584Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of HyperkalemiaColbert GSannapaneni SLerma EVGates Colbert,1 Shilpa Sannapaneni,1 Edgar V Lerma2 1Department of Internal Medicine, Division of Nephrology, Texas A&M College of Medicine, Dallas, TX, USA; 2Department of Internal Medicine, Division of Nephrology, University of Illinois at Chicago College of Medicine, Chicago, IL, USACorrespondence: Gates Colbert, 3417 Gaston Ave, Suite 875, Dallas, TX, 75246, Tel +972-388-5970, Fax +972-388-5971, Email Gates.Colbert@BSWHealth.orgAbstract: Hyperkalemia remains one of the most difficult consequences of disease state and treatment for patients with chronic kidney disease, heart failure, and diabetes. Controlling hyperkalemia can be difficult, but has become easier with the introduction of novel oral potassium binders. Patiromer was approved in 2015 for the treatment of hyperkalemia by the FDA in the United States. Several pivotal trials proved its efficacy, safety, and improved tolerability compared with previous hyperkalemia treatments. Additionally, many real-world publications and trials have given deeper insights into the capabilities of patiromer. We discuss improved disease state outcomes with combining patiromer with RAASi. This paper will also highlight new trials forthcoming that are highly anticipated to expand the possibilities in using patiromer to improve outcomes and populations.Keywords: hyperkalemia, chronic kidney disease, patiromer, proteinuriahttps://www.dovepress.com/clinical-efficacy-safety-tolerability-and-real-world-data-of-patiromer-peer-reviewed-fulltext-article-DHPShyperkalemiachronic kidney diseasepatiromerproteinuria |
| spellingShingle | Colbert G Sannapaneni S Lerma EV Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia Drug, Healthcare and Patient Safety hyperkalemia chronic kidney disease patiromer proteinuria |
| title | Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia |
| title_full | Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia |
| title_fullStr | Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia |
| title_full_unstemmed | Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia |
| title_short | Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia |
| title_sort | clinical efficacy safety tolerability and real world data of patiromer for the treatment of hyperkalemia |
| topic | hyperkalemia chronic kidney disease patiromer proteinuria |
| url | https://www.dovepress.com/clinical-efficacy-safety-tolerability-and-real-world-data-of-patiromer-peer-reviewed-fulltext-article-DHPS |
| work_keys_str_mv | AT colbertg clinicalefficacysafetytolerabilityandrealworlddataofpatiromerforthetreatmentofhyperkalemia AT sannapanenis clinicalefficacysafetytolerabilityandrealworlddataofpatiromerforthetreatmentofhyperkalemia AT lermaev clinicalefficacysafetytolerabilityandrealworlddataofpatiromerforthetreatmentofhyperkalemia |